Valuation: Minerva Neurosciences, Inc.

Market Cap 116M 104M 94.71M 86.46M 163M 10.86B 168M 1.14B 455M 5.8B 434M 424M 18.3B P/E 2026 *
-0.97x
P/E 2027 * -3.56x
Enterprise Value 116M 104M 94.71M 86.46M 163M 10.86B 168M 1.14B 455M 5.8B 434M 424M 18.3B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.74%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Minerva Neurosciences, Inc.

1 day+5.22%
1 week+4.31%
Current month+4.31%
1 month-24.84%
3 months-43.33%
6 months-58.84%
Current year-39.80%
1 week 2.2
Extreme 2.2
2.66
1 month 1.96
Extreme 1.96
3.23
Current year 1.96
Extreme 1.96
8.8
1 year 1.96
Extreme 1.96
8.8
3 years 1.15
Extreme 1.15
13.49
5 years 1.15
Extreme 1.15
15.27
10 years 1.15
Extreme 1.15
121.72
Manager TitleAgeSince
Chief Executive Officer 65 2014-10-31
Director of Finance/CFO 60 2021-10-10
Chief Tech/Sci/R&D Officer - 2021-09-15
Director TitleAgeSince
Chairman 65 2017-11-30
Director/Board Member 76 2014-06-30
Director/Board Member 63 2015-05-17
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Other

Chief Operating Officer

1,614,597 3.4656%
8/10/26 Other

Controller/Auditor

526,600 1.1303%
8/3/26 Free

Director

12,147 0.0261%
Change 5-day change 1-year change 3-year change Capi.($)
+5.22%+4.31%-34.77%-53.82% 116M
-4.83%+3.51%+55.00%+62.02% 66.7B
+0.02%+1.07%+11.72%+74.73% 56.88B
-1.34%+2.98%+25.08%+98.39% 56.53B
+5.09%+9.89%+27.19%+103.27% 46.49B
+2.62%+1.68%+29.16%+36.08% 44.8B
+8.24%+0.51%+215.16%+807.84% 41.59B
-1.86%+10.13%+28.14%+53.61% 35.35B
-2.97%-9.84%+90.91%+61.94% 33.29B
+5.19%+1.62%-39.69%+381.71% 25.1B
Average +1.54%+2.81%+40.79%+162.57% 40.68B
Weighted average by Cap. +0.65%+3.07%+49.88%+165.90%

Financials

2026 *2027 *
Net sales - -
Net income -130M -116M -106M -96.98M -183M -12.18B -188M -1.28B -511M -6.5B -486M -476M -20.52B -54.45M -48.84M -44.63M -40.74M -76.76M -5.12B -79.18M -538M -215M -2.73B -204M -200M -8.62B
Net Debt - -
Projected Income Statement - Annual - Minerva Neurosciences, Inc.
Logo Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Employees
7
Date Price Change Volume
26-11-06 US$2.420 +5.22% 238,042
26-11-05 US$2.300 -10.51% 182,094
26-11-04 US$2.570 +9.36% 308,643
26-11-03 US$2.350 +0.21% 240,552
26-11-02 US$2.345 +1.08% 230,596
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Minerva Neurosciences, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
2.420USD
Average target price
10.33USD
Spread / Average Target
+327.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Minerva Neurosciences, Inc.
  1. Stock Market
  2. Stocks
  3. NERV Stock